Modified FORM PTO-1449	SEP 2 5 7006 W	ATTY. DOCKET NO. NEU-102.1P US	SERIAL NO. 10/549,488	
LIST OF PATENTS AND PUBLICATION OF PATENTS AND PUBLICATION DISCLOSURE STATEMENT		APPLICANT KATZMAN et al.		
(Use several sheets	if necessary)	FILING DATE 7/31/2006	GROUP 3762	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/AP/	AA	U.S. 4,177,290	12/4/79	Lafon			3/9/1978
	AB	U.S. 4,927,855	5/22/90	Lafon			1/28/1987
	AC	U.S. 5,612,379	3/18/97	Laurent			4/30/1996
	AD	U.S. RE37,516 E.	1/15/02	Grebow et al.			4/1/1999
	AE	U.S. 6,463,328 B1	10/8/02	John			1/10/2000
	AF	U.S. 6,489,363 B2	12/3/02	Jacobs et al.			10/10/2001
	AG	U.S. 2002/0098240 A1	7/25/02	Jacobs et al.			10/11/2001
	AH	U.S. 2003/0022940 A1	1/30/03	Corvari et al.			5/23/2002
	ΑI	U.S. 2003/0125391 A1	7/3/03	Jacobs et al.			11/1/2002
	AJ	U.S. 2004/0048931 A1	3/11/04	Heacock et al.			7/10/2003
	AK	U.S. 2004/0105891 A1	6/3/04	Bentolila et al.	<u> </u>	<u> </u>	11/24/2003
V	AL	U.S. 2004/0116532 A1	6/17/04	Heacock et al.	1	†	9/11/2003

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSLATION YES N	0N 0N
BA							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/AP/	CA	Bastuji et al., Prog. Neuro-Psychopho	rmacol. & Biol. Psychiat., 12:695-700 (1988)		
	CB	Cass et al., Journal of Pharmaceutica	al and Biomedical Analysis, 26:123-130 (2001)		
	CC	Donovan et al., Therapeutic Drug Mo			
	CD	Duteil et al., European Journal of Ph	armacology, 180:49-58 (1990)		
	CE	In et al., Chem. Pharm. Bull., 52:118	6-1189 (2004)		
	CF	Physician's Desk Reference, 58th ed.	(Thomson PDR, Montvale, NJ) pages1160-1163 (2004)		
	CG		Rappaport et al., Arch. Phys. Med. Rehabil., 63:118-123 (1982)		
	СН	Saletu et al., Int. J. Clin. Pharm. Res., 9:183-195 (1989)			
	CI	Walker et al., Neuron, 44:121-133 (20	04)		
	CJ	Wisor et al., The Journal of Neuroscie	ence, 21:1787-1794 (2001)		
	CK	Wong et al., Journal of Clinical Pharmacology, 39:30-40 (1999)			
V	CL	Wong et al., Journal of Clinical Pharmacology, 39:281-288 (1999)			
EXAMINER	/An	nanda Patton/	DATE CONSIDERED 08/27/2007		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Modified FORM PTO-1449	ATTY. DOCKET NO. NEU-102.1P US	SERIAL NO. 10/549,488	
LIST OF PATENTS AND POBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Katzman et al.		
(Use several sheets if necessary)	FILING DATE July 31, 2006	GROUP 3762	

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/AP/	AA	4,927,855	05/22/1990	Lafon, L.			24.1.46.144.2
	AB	5,612,379	03/18/1997	Laurent, P.			
	AC	6,463,328	10/08/2002	John, M.			
	AD	6,489,363	12/03/2002	Jacobs et al.			
	AE	RE37,516 E	01/15/2002	Grebow et al.			
V	AF	US 2006/0135621	07/22/2006	Neckebrock et al.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/AP/	AG	Bastuji et al., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 12: 695-700 (1988)
	AH	Donovan et al., Ther. Drug Monit., 25(2): 197-202 (2003)
	AI	Duteil et al., Eur. J. Pharmacol., 180: 49-58 (1990)
	AJ	Physician's Desk Reference, 58th ed., (Thomson, Montvale, New Jersey, 2004), p. 1160-1163
	AK	Rappaport et al., Arch. Phys. Med. Rehabil., 63: 118-123 (1982)
	AL	Saletu et al., Int. J. Clin. Pharm. Res., 9: 183-195 (1989)
V	AM	Wisor et al., J. Neuroscience, 21(5): 1787-1794 (2001)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

/Amanda Patton/

08/27/2007

sheet _1_ of _1_